Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alcon AG (ALC) vs MasTec Inc (MTZ) Price & Performance

Alcon AG
MasTec Inc

Price performance

Price movement over the last 24 hours

Key statistics

Alcon AG vs MasTec Inc — how do they compare? Alcon AG trades at $66.86 (market cap $32.69B), while MasTec Inc trades at $380.65 (market cap $30.08B). The key difference: Alcon AG and MasTec Inc are close in size by market cap, and Alcon AG pays a 0.54% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.

ALCMTZ
Market Cap
$32.69B$30.08B
Sector
HealthTechnology
52-Week High
$92.22$437.51
52-Week Low
$62.02$168.24
Enterprise Value
$36.28B$32.82B
Dividend Yield
0.54%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alcon AG

ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.

The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.

MasTec Inc

MTZ trades at $380.63, up 1.93% today, with a neutral technical signal. The stock shows strong fundamental momentum, beating earnings estimates in three consecutive quarters, and holds a record $20.3 billion backlog. Recent news highlights a $1.65 billion acquisition of Superior Group to expand data center infrastructure capabilities, positioning the company for growth in AI-driven demand.

Outlook remains positive with 89% analyst buy ratings and a $476.62 consensus price target, implying 25% upside. Key risks include integration challenges from acquisitions and execution risks on large projects. Revenue growth is supported by infrastructure spending trends, but valuation multiples are elevated relative to industry peers.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alcon AG

Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.

Read more on ALC

About MasTec Inc

MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.

Read more on MTZ